mental conditions under which the acute, toxic response occurs; (ii) determine the importance of the mouse strain in susceptibility to the acute, toxic reaction; (iii) ascertain the involvement of immune complex formation in the acute, toxic effect; and (iv) identify pharmacological agents that prevent the acute, toxic reaction. Our results demonstrate that the toxicity is greatly influenced by the extent of cryptococcal infection; little or no toxicity was observed early in infection or late in infection when signs of central nervous system (CNS) involvement were evident. The toxic response occurred in some strains of mice but not in others. Finally, we found that the toxic response could be reduced or eliminated by use of several pharmacologic agents, most notably WEB 2170 BS, an antagonist of the receptor for platelet-activating factor (PAF).
phate coating buffer (0.05 M, pH 7.4). The wells were washed with 0.05 M NaPO 4 (pH 7.4) containing 10 mM EDTA and blocked by incubation for 90 min with 0.05 M NaPO 4 (pH 7.4) containing 0.05% Tween 20. Serial dilutions of sera from C. neoformans-infected mice were prepared in PBS containing 0.05% Tween 20 (PBS-Tween) and incubated for 90 min in the antibody-coated wells. The wells were washed with PBS-Tween and incubated for 90 min with an optimal dilution of a horseradish peroxidase conjugate of MAb 439. The wells were washed with PBS-Tween and incubated for 30 min with tetramethylbenzadene peroxidase substrate (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, Md.) according to the manufacturer's directions. The optical density at 450 nm was determined with a BIO-TEK Ceres 900 plate reader. The concentrations of GXM in the sera were calculated by comparison with a purified GXM standard.
Cryptococcal polysaccharide. GXM was isolated from C. neoformans 24064 serotype A (American Type Culture Collection, Rockville, Md.) and was used for all experiments requiring GXM. GXM was isolated from culture filtrates of the yeast grown on synthetic medium (13) and was purified by differential precipitation with ethanol and hexadecyltrimethylammonium bromide by using a modification (31) of a procedure originally described by Cherniak et al. (12) . Purified GXM was lyophilized and stored at room temperature. GXM was hydrated overnight and diluted as needed with sterile PBS made with endotoxin-free water.
Antibody production and purification. Mouse MAbs were isolated from ascites fluid. The immunoglobulin class and serotype specificity of each MAb are shown in Table 1 . The specific isolation procedure varied for each antibody, depending on the immunoglobulin class, IgG subclass, and the binding characteristics of the antibody. MAb isolation typically included various combinations of selective precipitation with caprylic acid (53) and ammonium sulfate, immunoaffinity purification with GXM-Sepharose (35) , and affinity chromatography with protein A-Sepharose (51) as appropriate. Rabbit anti-GXM antibodies were raised by immunization with a methylated bovine serum albumin conjugate of GXM (33) . Rabbit polyclonal antibodies were isolated by selective precipitation with caprylic acid and ammonium sulfate followed by immunoaffinity purification with GXM-Sepharose.
The MAb 439 subclass-switch MAb family (IgG13IgG2b3IgG2a) was isolated and produced in a manner identical to that of the MAb 471 subclass switch family described previously (51) . Subclass-switch antibodies were isolated from ascites fluid by selective precipitation with caprylic acid and ammonium sulfate followed by immunoaffinity purification with GXM-Sepharose. The purity of antibodies of each subclass was ensured by binding each MAb to protein ASepharose (3.0 M NaCl and 1.5 M glycine [pH 8.9]) followed by elution at decreasing pH. Elution from protein A-Sepharose was achieved by stepwise use of 0.1 M citric acid buffers at pH 6.0 for IgG1, at pH 5.0 for IgG2a, and at pH 4.0 for IgG2b. The MAb subclass was confirmed by an ELISA, described previously (31) , which was modified by use of second antibodies specific for murine IgG subclasses. F(ab) 2 fragments of MAb 439 were prepared with an immobilized Ficin kit, which was used according to the manufacturer's directions (Pierce, Rockford, Ill.); purity was confirmed by the presence of a single band by sodium dodecyl sulfate-polyacrylamide gel electrophoresis done under nonreducing conditions. Antibody concentrations were determined spectrophotometrically assuming an A 280 (1 mg/ml) of 1.43 for IgG and 1.18 for IgM (52) . The concentration of MAb 439 in filtered ascites fluid was determined by an ELISA with tyraminated GXM as an antigen (31) and immunoaffinity-purified MAb 439 as the standard. A nonspecific murine antibody with IgG1 heavy chains and kappa light chains (MOPC-21; Sigma) was used as a negative control. Antibodies were diluted immediately prior to injection in sterile PBS made with endotoxin-free water.
MAb 439 was used for most of the toxicity studies. The extent of contamination of this antibody preparation by endotoxin was determined by use of the Polychrome Limulus amebocyte lysate assay (Associates of Cape Cod, Inc., Woods Hole, Mass.) according to the manufacturer's directions.
Immune complex formation. Immune complexes were prepared in vitro by mixing MAb 439 (6.0 mg) with various quantities of GXM (24, 240, 2,400, and 11,000 g). The complexes were incubated for 30 min at 37ЊC, with mixing every 5 min. Immune complexes were injected intravenously in 200-l volumes.
Inhibition of acute toxicity. A variety of agents were evaluated in an attempt to block the acute, lethal toxicity. Cyproheptadine (Sigma), chlorpheniramine (Sigma), and ketanserin tartate (ICN Biomedicals, Costa Mesa, Calif.) were dissolved in sterile endotoxin-free water. Aminophylline (American Regent Laboratories, Shirley, N.Y.), chlorpromazine HCl (Steris Laboratories, Inc., Phoenix, Ariz.), N -nitro-L -arginine methyl ester (NAME; Sigma), and epinephrine (Anpro Pharmaceutical, Arcadia, Calif.) were diluted in sterile PBS made with endotoxin-free water. Dexamethasone (Burns Veterinary Supply, Rockville Centre, N.Y.) was used as supplied by the manufacturer. The PAF inhibitor, WEB 2170 BS, was a kind gift from Boehringer Ingelheim KG, Ingelheim am Rhein, Germany. Solutions of WEB 2170 BS were prepared immediately prior to use with sterile PBS made with endotoxin-free water.
Rabbit anti-mouse tumor necrosis factor alpha (TNF-␣) was purchased from Genzyme (Cambridge, Mass.). Antibody was injected at 2 ϫ 10 5 U per mouse. A preliminary experiment determined that intraperitoneal injection of 750 mg of lipopolysaccharide (LPS; catalog no. L-3129; Sigma) produced death in 100% of a group of otherwise healthy Swiss Webster (SW-CR) mice. Treatment of mice with 2 ϫ 10 5 U of anti-TNF-␣ antibodies protected mice from this lethal effect. Naja naja cobra venom factor (CVF) was purchased from Diamedix Corp. (Miami, Fla.). Preliminary experiments established that an intraperitoneal injection of 5 U completely depleted the ability of serum from CVF-treated mice to support activation and binding of radiolabeled C3 to C. neoformans for a minimum of 24 h.
Liposomes containing dichloromethylene diphosphonate (L-Cl 2 MDP; 40 mg/ ml) were a kind gift from Yong Moon Han, Montana State University, Bozeman, Mont. The preparation and use of L-Cl 2 MDP to deplete macrophages have been described previously (58, 59) .
Histopathology. Tissues (kidneys, small and large intestines, livers, lungs, brains, and spleens) were harvested immediately after animals succumbed to the lethal toxicity. Uninfected control mice were euthanized by cervical dislocation 90 min after treatment with MAbs, and the tissues were harvested. The tissues were washed in PBS and fixed in buffered Formalde-Fresh (Fisher Scientific, Pittsburgh, Pa.). Organs were embedded in paraffin, sectioned, and stained with hematoxylin and eosin.
Statistics. Statistical comparisons of the numbers of deaths in experimental groups were accomplished by use of a z-test with a 95% confidence interval computed with the assistance of SigmaStat for Windows (Jandel Scientific, San Rafael, Calif.). Determinations of the 50% lethal dose (LD 50 ) of MAb classswitch antibodies were done with a four-parameter logistic equation computed with the assistance of Prism (GraphPad Software, Inc., San Diego, Calif.).
RESULTS
Induction of acute toxicity. In studies of the efficacy of passive immunization with anticryptococcal MAbs, we observed the occurrence of an acute, lethal toxicity in SW-CR mice infected with C. neoformans. Uninfected mice treated with MAb 439 alone were unaffected. An initial experiment was done to identify the stage of the infection at which mice became susceptible to the toxic effect. Mice were infected intravenously with 10 6 cryptococcal cells, and MAb 439 (0.5 mg) was injected intraperitoneally into separate groups of mice (10 mice per group) at various times during the course of infection. Animals were observed for 3 h after challenge with MAbs. The results (Fig. 1) showed that the acute, lethal toxicity was most evident during the midstage of the cryptococcal infection. The acute reaction was characterized by scratching, distressed breathing, loss of coordination, lethargy, and collapse and generally resulted in death within 20 to 60 min after injection of the MAb. The lethal toxicity was less frequent early in infection and late in infection when signs of CNS involvement, such as hydrocephalus, were apparent (day 20). Mice that survived the toxic effect 1 h past challenge with MAb recovered fully.
A parallel group of 10 C. neoformans-infected mice was examined for serum levels of GXM at the same time intervals at which the toxicity of MAb 439 was assessed. The results ( Fig.  1 ) showed a mean serum GXM level of approximately 9 g of GXM per ml of serum at day 12 of infection, the time at which the toxic response to challenge with MAb was at a maximum. Histopathological analysis of tissues from mice succumbing to lethal toxicity showed pathological changes in the lungs, livers, spleens, intestines, and kidneys. Results from the lung, livers, and kidney are shown in Fig. 2 . Minimal pathological changes were observed in tissues from uninfected mice that were treated with MAb. All tissues from infected mice challenged with MAb 439 showed vascular dilation and hyperemia. Marked congestion was observed in the liver, kidney, and intestine. The lungs showed marked congestion with intraalveolar hemorrhage. The brain appeared unaffected. The involvement of multiple systems, particularly the respiratory and vascular systems, indicate that the mice died of a shock-like syndrome.
There are several explanations for the acute toxicity produced by passive immunization in murine cryptococcosis that are unrelated to the antigen-binding activity of MAb 439. An initial experiment examined the possibility that the ability of MAb 439 to produce acute, lethal toxicity was an artifact created by the procedures used to isolate and purify the antibody. SW-CR mice (10 mice per group) were infected intravenously with 10 6 yeast cells and passively immunized 8 days after infection with 0.5 mg of MAb 439 as either crude ascites fluid or as purified antibody. The amount of antibody in the ascites fluid was determined by ELISA with GXM as the antigen and purified MAb 439 as the standard. Both antibody preparations induced similar toxic responses at two different dose levels in C. neoformans-infected mice (Fig. 3 ).
An alternative explanation for the toxic activity of the MAb preparations in C. neoformans-infected mice is the presence of endotoxin contamination. MAb 439 was isolated from ascites fluid and subjected to several purification steps that introduced low levels of endotoxin into the antibody preparation. Analysis of the MAb 439 preparation used for the experiment for which the results are shown in Fig. 1 showed the presence of approximately 20 ng of endotoxin per mg of antibody, indicating that mice (results shown in Fig. 1 ) received approximately 10 ng of endotoxin (approximately 0.5 g/kg of body weight). In an effort to determine the ability of endotoxin to elicit the observed acute toxicity, mice were infected intravenously with 10 6 yeast cells and challenged on day 12 of infection with 500 g of MAb 439 or 500 ng of endotoxin (approximately 25 g/kg). One hundred percent mortality occurred in the group of mice treated with MAb 439 (mortality, 10 of 10 mice) whereas neither symptoms of acute toxicity nor deaths occurred in mice treated with endotoxin (mortality, 0 of 5 mice). In contrast, approximately 750 g of LPS (37 g/kg) was required to produce 100% mortality in healthy Swiss Webster mice (data not shown).
Influence of mouse strain on susceptibility to acute toxicity. Previous studies of passive immunization in murine cryptococcosis done by other laboratories did not note the occurrence of acute toxicity (21, 40, 41) . We considered the possibility that susceptibility to acute toxicity could be influenced by the strain of mouse. Consequently, we examined the BALB/c, C57BL/6, C3H/He, and DBA/2 strains as well as SW-CR and SW-S mice. The inoculum used to establish the cryptococcal infection was reduced to 10 5 yeast cells because higher inocula have been shown to produce a rapidly lethal cryptococcal pneumonia in C5-deficient mice such as DBA/2 (46). Mice were infected on day 0, and groups of mice (10 mice per group) were passively immunized with 0.5 mg of MAb 439 on days 6, 10, 14, 18, or 22 after infection and observed for the occurrence of lethal toxicity. The results (Fig. 4) showed striking variation in susceptibility to MAb-induced lethal toxicity. The strains can be ranked in order from highest to lowest susceptibility to lethal toxicity as follows: SW-CR Ͼ C3H/He Ͼ BALB/c Ͼ C57BL/ 6 Ͼ DBA/2 ϭ SW-S. Variability in susceptibility to toxicity could not be attributed to marked differences in susceptibility to cryptococcosis. A group of 8 to 10 control mice from each strain were infected with C. neoformans but not treated with MAb. Mortality due to cryptococcosis in this infected but untreated control group is also shown in Fig. 4 . Mice from all strains except DBA/2 succumbed to the cryptococcal infection within comparable time frames (median time of death of 18 to 24 days). The DBA/2 mice were slightly more resistant to cryptococcosis, with a median time of death of 33 days.
Role of antibody specificity and isotype in production of the toxic effect. The ability of anti-GXM antibodies with different serotype specificities, immunoglobulin class, or species of origin to induce toxicity was evaluated in an effort to determine whether the toxicity that followed passive immunization was unique to MAb 439 or was a general phenomenon that could be induced by any antibody reactive with GXM. On day 8 of infection, mice were challenged intraperitoneally with one of the purified antibodies (0.5 mg). The results (Table 1) showed that all MAbs of the IgG class (MAbs 439, 471, 1255, 302, and 3C2) induced acute, lethal toxicity of 60% or greater. Affinitypurified rabbit anti-GXM IgG was also toxic (80% mortality). In contrast, MAb 386, an IgM antibody with a serotype specificity similar to that of MAb 302, and F(ab) 2 fragments prepared from MAb 439 did not elicit an observable toxic response in the mice. No toxicity was noted in mice treated with MOPC-21, a nonspecific murine antibody with no reactivity for GXM.
Two families of subclass-switch antibodies derived from MAbs 439 and 471 were evaluated in a dose-response study to assess the role of IgG subclass in the ability to induce lethal toxicity. The results from study of the MAb 439 subclass-switch family (Table 2) showed that antibodies of the IgG1, IgG2a, and IgG2b subclasses were toxic over a broad dose range. The (Fig. 5) showed acute, lethal toxicity in mice pretreated with GXM and challenged with MAb via the intravenous route. Mice treated with either GXM or MAb alone were unaffected. Mice passively immunized via the intraperitoneal route exhibited symptoms of toxicity, such as scratching and lethargy, but no deaths occurred. We also evaluated the toxicity of immune complexes formed in vitro. GXM-MAb immune complexes were prepared in vitro and injected via the intravenous route into SW-CR mice (10 mice per group). As in animals pretreated with GXM, the acute toxicity that occurred in C. neoformans-infected mice could be mimicked with immune complexes (Fig. 6 ). The lethal effect was dependent on the GXM concentration. Immune complexes containing 2 and 20 g of GXM complexed with 0.5 mg of MAb produced a mortality rate of 20%, whereas complexes containing 200 and 1,000 g of GXM induced mortality rates comparable to those observed following passive immunization in infected mice (70 and 100%, respectively).
Inhibition of toxicity. Immune complexes activate the complement system and generate inflammatory mediators, particularly C5a. As a consequence, we evaluated the role of the complement system in production of the toxic effect. CVF was used on day 7 of infection to deplete C3 and C5 (14) . The results showed that treatment with CVF did not protect mice from the toxic effect (Table 3) .
Macrophages are one means of clearance of immune complexes from the circulatory system and are an important source of cytokines such as TNF-␣, PAF, and interleukin-1 (IL-1) (6, 11, 18) . Our results led us to hypothesize that macrophages were activated upon interaction with the Fc region of the MAb in the immune complex, inducing release of intermediates responsible for initiating the acute, lethal toxicity. Accordingly, we evaluated the production of acute, lethal toxicity in mice that were treated with L-Cl 2 MDP, a procedure which depletes macrophages in the liver and spleen (59) . The results (Table  3) show that treatment of mice with L-Cl 2 MDP completely blocked the development of acute, lethal toxicity. Moreover, mice treated with L-Cl 2 MDP showed no visible signs of toxicity or distress after challenge with MAb.
Several pharmacological modulators were evaluated for their ability to control or block the toxicity (Table 3) . The dosages and routes of administration were based on published reports of use of each agent in rodent systems. Treatment with anti-mouse TNF-␣, cyproheptadine, ketanserin tartate, aminophylline, NAME, and chloropheniramine failed to block the acute, lethal toxicity. Toxicity was reduced by treatment of mice with epinephrine, dexamethasone, or chlorpromazine, but only at very high drug doses. Toxicity was completely blocked by treatment with WEB 2170 BS, an antagonist of PAF.
DISCUSSION
Passive immunization with anti-GXM MAbs decreases the fungal burden and reduces mortality in C. neoformans-infected mice (20, (39) (40) (41) . Our studies show that, with an appropriate combination of circumstances, passive immunization in experimental cryptococcosis may elicit an immediately lethal outcome. Histopathologic studies showed multisystem involvement with hyperemia. All available evidence indicates that death was due to immune complex-induced systemic shock. Such toxic responses were not noted in previous reports of passive immunization in murine cryptococcosis. There are two possible explanations for this apparent discrepancy. Dromer et al. (20, 21) a Results are reported as the number of deaths from acute toxicity/number of mice in each group. SW-CR mice were infected with C. neoformans on day 0. On day 8 of infection, mice were challenged intraperitoneally with MAb.
b The 95% confidence interval for the LD 50 is given in parentheses.
repeated the treatment every 24 h for 5 days. Mukherjee et al. (39) (40) (41) administered antibody as early as 48 h prior to or 24 h after infection. In our studies, the cryptococcal infection was allowed to progress a minimum of 4 days before MAb treatment. The quantity of polysaccharide available in vivo to form soluble immune complexes was undoubtedly much greater in our model than in previous reports. Various strains of mice exhibited markedly different susceptibilities to the toxic effect. There are several possible explanations for this variable effect. First, the strains of mice could process GXM differently. Second, differences in animal husbandry or exposure to LPS produced by enteric bacteria may influence susceptibility to lethal toxicity. Finally, the strains of mice could differ in their responses to effectors of the toxic effect. A detailed explanation will require additional experimentation that involves more strains of mice, an examination of the course of cryptococcosis and processing of GXM, an assessment of susceptibility to toxic mediators, and a genetic analysis of inheritance of susceptibility to the toxic effect.
Several characteristics of a MAb which were necessary for induction of toxicity were identified. A molecular and idiotypic analysis of heavy-and light-chain variable regions of anti-GXM antibodies identified five distinct groups of anti-GXM MAbs (9) . Such groups of antibodies differed in their serotype specificities and their molecular structures. We examined IgG MAbs representative of three of these groups and found that all of the IgG antibodies were able to induce acute, lethal toxicity. Thus, within the limitations of the experimental design, fine epitope specificity was not an important parameter. Acute toxicity could not be attributed to the species of origin of the anti-GXM IgG because rabbit polyclonal anti-GXM IgG also induced the toxic response. The most significant determinant for the toxic potential of an anti-GXM antibody was the presence of an intact IgG Fc region. IgM MAbs and F(ab) 2 fragments produced from an IgG1 antibody failed to induce the lethal toxicity. The actual IgG subclass was not a significant variable because similar toxic responses were noted after passive immunization with IgG2a and IgG2b subclass-switch variants of IgG1 MAbs 439 and 471.
The ability of various agents to block the toxic response provides some direction as to the cellular and molecular effector mechanisms for the acute, lethal toxicity. Cyproheptadine, ketanserin tartate, chlorpheniramine, and aminophylline failed to block the toxic response. Although the dosages and routes of administration of these agents were based on published results from rodent systems, it is possible that one or more of these agents might fail to produce the expected effect in SW-CR mice. Nevertheless, the collective lack of effect of these agents strongly suggests that the toxic response is not due to histamine or serotonin release. Complement depletion by treatment with CVF did not block the acute, lethal effect, indicating that the release of by-products of complement activation, such as C3a and C5a, is not necessary for toxicity. Failure to elicit the toxic response by passive immunization with an IgM MAb also argues against a role for complement activation.
Macrophages clear immune complexes from the circulation via Fc receptors. Consequently, we considered the possibility that phagocytic cells play a central role in the toxic response. A macrophage suicide technique was used to identify involvement of macrophages in the acute, lethal toxicity. Intravenous injection of L-Cl 2 MDP selectively eliminates macrophages of the spleen and liver (59) . The absence of acute toxicity in L-Cl 2 MDP-treated mice clearly implicates macrophage involvement. This result is consistent with the absence of toxicity in mice challenged with anti-GXM IgM and F(ab) 2 fragments of anti-GXM IgG.
Activation of macrophages by immune complexes initiates the release of nitric oxide (38) and many cytokines, including TNF, IL-1, and PAF (6, 11, 18) . Nitric oxide and many of these cytokines have been linked to systemic shocks including anaphylaxis and endotoxin shock resulting in multiple organ failure (6, 15, 43, 57) . Of particular interest is the observation that immune complexes of GXM and MAbs specific for GXM induce nitric oxide production by gamma interferon-stimulated murine macrophage-like J774.16 cells (38) . However, the failure of the nitric oxide inhibitor NAME to block the toxic effect indicates that nitric oxide is not the primary mediator. Toxicity was reduced or eliminated by treatment of mice with dexamethasone and chlorpromazine. Chlorpromazine and dexamethasone protect against LPS toxicity by their ability to decrease TNF production (24) . Chlorpromazine also down-regulates production of IL-2, gamma interferon, IL-4, and TNF and up-regulates IL-10 secretion (56). Failure to reduce toxicity by treatment with anti-TNF-␣ antibodies does not necessarily exclude a role for TNF-␣ in the acute, toxic response. Studies of TNF-␣ in LPS-mediated toxicity found that the protective activity of anti-TNF-␣ antibody is easily overwhelmed by increased doses of LPS (2) . Given the magnitude and acute nature of the toxic effect associated with passive immunization, a failure of anti-TNF-␣ antibodies to protect would not be surprising.
Acute, lethal toxicity following passive immunization was blocked by treatment of mice with WEB 2170 BS (nonproprietary name: bepafant). WEB 2170 is a potent and specific competitive antagonist of PAF (10, 29) . This result demonstrates that PAF has a primary role in the toxic effect. A role for PAF in toxicity associated with passive immunization is similar to the results found by Bleeker et al. (6) , who found PAF to be the dominant mediator of hypotension and increased vascular permeability after intravenous injection of immunoglobulin preparations. Toxicity observed after passive immunization resembled several features of the rat anaphylactic response to soluble immune complexes (18) . First the time courses were similar. Intravenous injection of soluble immune complexes into rats was followed within 5 to 10 min by the development of hypotension and extravasation. Second, hypotension and extravasation induced by immune complexes were almost completely blocked by treatment of the rats with the PAF antagonist L-652,731. It was this response of the immune complex-induced hypotension and extravasation to a PAF inhibitor which first called our attention to PAF antagonists for prevention of toxicity associated with passive immunization. Third, infusion of immune complexes into rats with blocked liver circulation produced no extravasation. This latter observation is consistent with our result that toxicity associated with passive immunization is blocked by ablation of liver and splenic macrophages. Finally, the extravasation response to immune complexes was inhibited by dexamethasone but not by inhibitors of histamine and serotonin receptors, results that are identical to the effects of these agents on toxicity associated with passive immunization in murine cryptococcosis.
An alternative explanation for the toxicity associated with passive immunization is the possibility that the toxic response is due to the presence of endotoxin in the MAb preparation. The amount of endotoxin contained in the dose of MAb 439 used for passive immunization (10 ng of endotoxin) is well below the amount required to produce death in healthy Swiss Webster mice used in this study (750 g of endotoxin); however, it is possible that endotoxin could produce a toxic effect in C. neoformans-infected mice. For example, sensitization of mice by pretreatment with zymosan or Bacillus Calmette Guérin bacilli primes rats for production of shock, leukopenia, and bowel injury in response to challenge with relatively low doses of LPS (54) . Several factors argue against endotoxin contamination of the MAb preparation as the primary factor in producing the toxic effect. First, injection of purified LPS into C. neoformans-infected mice in amounts approximately 50 times greater than would have been contained in the MAb preparation had no apparent toxic effect. Second, the time course of the toxic response in passive immunization was much more rapid than has been reported in LPS-dependent effects. LPS-induced lethality occurred 12 to 48 h after intraperitoneal injection into healthy Swiss Webster mice used in the current study, a time frame that is consistent with reports from other laboratories (25) . Even models of hypersensitivity to the lethal effects of LPS required considerably more time than the lethal toxicity associated with passive immunization. For example, one or more hours was required to produce hypotension in LPS-treated rats that were primed with zymosan (54). Similarly, sensitization of mice by pretreatment with galactosamine reduced the lethal dose of LPS by a factor of at least 30,000, but the majority of deaths occurred between 5 and 9 h after injection of LPS (25) . Finally, the absence of toxicity in mice passively immunized with an MAb of the IgM class or with F(ab) 2 fragments of a normally toxic MAb identify an intact IgG Fc fragment as an essential determinant of the toxic effect. We cannot rule out LPS from either an endogenous source, e.g., normal flora, or as a contaminant of the MAb preparation as a contributor to the toxic effect, but the preponderance of evidence indicates that the primary effect is due to formation of immune complexes and induction of a subsequent Fc-dependent effect.
Implications of toxicity associated with passive immunization for eventual use of passive immunization in treatment of human cryptococcosis are difficult to determine. The serum GXM levels in individual mice succumbing to the toxic effect was not determined. However, an examination of GXM in serum in a parallel cohort of C. neoformans-infected mice suggests that the toxic response occurred over a broad range of GXM levels in serum (Fig. 1) . It is unlikely that the levels in serum found in murine cryptococcosis differ greatly from levels found during cryptococcosis in humans. The marked variability in susceptibility of different strains of mice to the toxic effect raises a question as to whether humans are susceptible to the toxicity. Studies of toxicity in different species such as rats or guinea pigs might be useful in this regard. Our results indicate that toxicity can be avoided by selecting an antibody of an appropriate isotype. Specifically, anti-GXM IgM did not elicit a toxic response. MAbs of the IgM isotype are protective against murine cryptococcosis (39) . The effector mechanism for passive immunization with IgM is not known but presumably does not involve interaction with Fc receptors. This may allow IgM antibodies to be employed in passive immunization without a toxic consequence. Nevertheless, given the high levels of serum GXM found during disseminated infection, the possibility of immune complex-induced toxicity should be considered in passive immunization for treatment of cryptococcosis.
